PULMONARY PHARMACOLOGY & THERAPEUTICS
Scope & Guideline
Exploring the forefront of respiratory pharmacology.
Introduction
Aims and Scopes
- Pharmacological Innovations in Respiratory Diseases:
The journal emphasizes novel pharmacological agents and therapies for managing various respiratory diseases, including asthma, COPD, pulmonary hypertension, and cystic fibrosis. - Drug Delivery Systems:
A significant focus is placed on the development and evaluation of drug delivery systems, including inhalation techniques, formulations, and devices, aimed at optimizing therapeutic outcomes for respiratory conditions. - Mechanistic Studies of Lung Pathophysiology:
Research articles frequently explore the cellular and molecular mechanisms underlying lung diseases, contributing to a deeper understanding of pathophysiology and informing therapeutic strategies. - Clinical Efficacy and Safety Evaluations:
The journal publishes studies assessing the efficacy and safety of existing and emerging therapies, often through systematic reviews, meta-analyses, and real-world studies. - Interdisciplinary Approaches to Respiratory Health:
Encouraging interdisciplinary research, the journal integrates insights from pharmacology, immunology, microbiology, and clinical practice to address complex respiratory health issues.
Trending and Emerging
- Targeted Therapies and Personalized Medicine:
There is a growing trend towards exploring targeted therapies and personalized medicine approaches for chronic respiratory diseases, particularly in conditions like asthma and cystic fibrosis. - Innovations in Drug Delivery Technologies:
Research on novel drug delivery systems, including lipid nanoparticles and advanced inhalation devices, is trending, showcasing the need for effective and patient-friendly therapeutic options. - Impact of COVID-19 on Pulmonary Pharmacotherapy:
The ongoing implications of the COVID-19 pandemic have led to increased research on its effects on existing pulmonary disease management, including the use of existing therapies in COVID-19 patients. - Role of Biomarkers in Disease Management:
Emerging studies are increasingly focusing on the identification and utilization of biomarkers to predict treatment responses, disease progression, and therapeutic outcomes in respiratory conditions. - The Intersection of Immunology and Respiratory Diseases:
Research exploring the immunological aspects of respiratory diseases, particularly in the context of inflammation and fibrosis, is on the rise, reflecting a broader understanding of disease mechanisms.
Declining or Waning
- Traditional Antibiotic Therapies:
Research on conventional antibiotic therapies for respiratory infections is becoming less frequent, as newer agents and novel treatment modalities gain attention and importance. - Basic Research on Lung Physiology without Therapeutic Context:
Studies purely focused on the basic physiology of lung function, without direct implications for therapeutic advancements, are appearing less often, signaling a shift towards more clinically relevant research. - Generalized Asthma Management Approaches:
While asthma remains a key area of research, there is a noticeable decline in studies focusing on generic management approaches, with a growing interest in targeted therapies and personalized medicine.
Similar Journals
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Advancing respiratory health through cutting-edge research.American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.
Turkish Thoracic Journal
Connecting global insights to Turkish thoracic challenges.Turkish Thoracic Journal, published by AVES, is a prominent open-access platform dedicated to advancing the field of pulmonary and respiratory medicine. Since its establishment, the journal has aimed to disseminate significant research findings, clinical studies, and reviews that contribute to an improved understanding of respiratory health challenges, with a particular focus on the Turkish context and regional issues. With an E-ISSN of 2149-2530 and transitioning to open access in 2022, the journal enhances visibility and accessibility, inviting a global audience of researchers, clinicians, and students to engage with the latest scientific work. The Turkish Thoracic Journal has been indexed in major databases, although it faced a coverage discontinuation in Scopus between 2016 and 2022. Currently positioned within the 23rd percentile among its peers in the field, it invites submissions that explore innovative approaches to thoracic health, enriching the discourse in a vital area of medicine.
THORAX
Uncovering breakthroughs in lung health and disease.THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine
Innovating Clinical Insights for Better Patient OutcomesClinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine, published by SAGE Publications Ltd, stands as a vital resource in the fields of Cardiology and Pulmonary Medicine, underscored by its Q3 quartile rankings in both areas for 2023. Established in 2007 as an open-access journal, it facilitates the dissemination of cutting-edge research and observations from the international scientific community. With an ISSN of 1179-5484, the journal has garnered recognition for its contributions to clinical medicine, particularly covering topics of circulatory, respiratory, and pulmonary health. The journal not only aims to bridge the gap between research and clinical practice but also to serve as a platform for innovative ideas and collaborations among researchers, healthcare professionals, and trainees. By offering unrestricted access to its articles, Clinical Medicine Insights ensures that vital knowledge reaches a broad audience, ultimately fostering advancements in medical science and patient care.
BMC Pulmonary Medicine
Exploring groundbreaking discoveries in respiratory medicine.BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.
Annals of Thoracic Medicine
Advancing knowledge in thoracic health.Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.
Therapeutic Advances in Respiratory Disease
Exploring New Frontiers in Respiratory TherapeuticsTherapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.
PEDIATRIC PULMONOLOGY
Advancing pediatric respiratory health through innovative research.Pediatric Pulmonology is a leading journal published by Wiley, dedicated to advancing the field of pediatric respiratory medicine. With an impressive impact factor and a commitment to excellence since its inception in 1985, this quarterly publication reaches researchers, clinicians, and healthcare professionals interested in the latest findings and practices concerning pediatric pulmonary health. The journal has achieved notable rankings in prestigious databases, including Q1 in Pediatrics, Perinatology, and Child Health, and Q2 in Pulmonary and Respiratory Medicine, reflecting its high-quality contributions to the field. Celebrated for its rigorous peer-review process, Pediatric Pulmonology serves as a vital platform for disseminating significant research, clinical studies, and innovative approaches to the management of respiratory conditions in infants, children, and adolescents. This journal not only provides valuable insights but also fosters collaboration among professionals dedicated to enhancing the care and outcomes for young patients. Access to this resource is available through institutional subscriptions, further ensuring widespread dissemination of crucial research findings.
EUROPEAN RESPIRATORY JOURNAL
Pioneering Research for Better BreathingThe EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.
LUNG
Championing excellence in respiratory research and education.LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.